Intracellular metabolic pathways dependent on the mammalian Target Of Rapamycin (mTOR) play a key role in immune-tolerance control. In this study, we focused on long term mTOR-dependent immune-modulating effects in kidney transplant recipients undergoing conversion from Calcineurin inhibitors (CNI) to mTOR inhibitors (Everolimus), in a one-year follow-up. The conversion to Everolimus is associated with a decrease of neutrophils and of CD8+ T cells. In addition, we observed a reduced production of Interferon(IFN)-γ by CD8+ T cells and of Interleukin(IL)-17 by CD4+ T lymphocytes. An increase in CD4+ CD25+ Foxp3+ (Treg) number was also seen. Treg increase correlated with a higher proliferation rate of this regulatory subpopulation, when compared with the CD4+ Foxp3- effector counterpart. Basal phosphorylation level of S6 kinase, a major mTOR-dependent molecular target, was substantially maintained in patients treated with Everolimus. Moreover, oscillations in serum concentration of Everolimus were associated with changes in basal and activation-dependent S6 kinase phosphorylation of CD4+ and CD8+ T cells. Indeed, T Cell Receptor (TCR) triggering was observed to induce significantly higher S6 kinase phosphorylation in the presence of lower Everolimus serum concentrations. These results unveil the complex mTOR-dependent immune-metabolic network leading to long-term immune-modulation and might have relevance for novel therapeutic settings in kidney transplants.

Oscillatory mTOR inhibition and Treg increase in kidney transplantation.

PALATUCCI, ANNA TERESA;GIOVAZZINO, ANGELA;TERRAZZANO, Giuseppe
2015-01-01

Abstract

Intracellular metabolic pathways dependent on the mammalian Target Of Rapamycin (mTOR) play a key role in immune-tolerance control. In this study, we focused on long term mTOR-dependent immune-modulating effects in kidney transplant recipients undergoing conversion from Calcineurin inhibitors (CNI) to mTOR inhibitors (Everolimus), in a one-year follow-up. The conversion to Everolimus is associated with a decrease of neutrophils and of CD8+ T cells. In addition, we observed a reduced production of Interferon(IFN)-γ by CD8+ T cells and of Interleukin(IL)-17 by CD4+ T lymphocytes. An increase in CD4+ CD25+ Foxp3+ (Treg) number was also seen. Treg increase correlated with a higher proliferation rate of this regulatory subpopulation, when compared with the CD4+ Foxp3- effector counterpart. Basal phosphorylation level of S6 kinase, a major mTOR-dependent molecular target, was substantially maintained in patients treated with Everolimus. Moreover, oscillations in serum concentration of Everolimus were associated with changes in basal and activation-dependent S6 kinase phosphorylation of CD4+ and CD8+ T cells. Indeed, T Cell Receptor (TCR) triggering was observed to induce significantly higher S6 kinase phosphorylation in the presence of lower Everolimus serum concentrations. These results unveil the complex mTOR-dependent immune-metabolic network leading to long-term immune-modulation and might have relevance for novel therapeutic settings in kidney transplants.
2015
File in questo prodotto:
File Dimensione Formato  
mTOR cei12669.pdf

accesso aperto

Tipologia: Pdf editoriale
Licenza: DRM non definito
Dimensione 634.91 kB
Formato Adobe PDF
634.91 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11563/112307
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact